All entries for: Oncology

April 30, 2026

Autolus Therapeutics

Layoffs

London

501-1,000 employees

In a move aimed at improving operational efficiency and cutting costs, London-based Autolus Therapeutics is letting go of about 13% of employees, the company announced April 29. The biotech, which develops autologous CAR T therapies, did not identify which locations the workforce reduction will affect but noted that it will impact all areas of the business. Autolus has a U.S. presence through its Gaithersburg, Maryland, office.

While the company said it’s cutting 13% of the workforce, it also noted that the reorganization includes “employee-related actions taken beginning in the second half of 2025.” When asked to clarify that statement, a spokesperson told BioSpace in an email that some employees were let go in the second half of last year, but “the number didn’t rise to the level of ‘material’ thus there was no announcement.” Those cuts, they added, count as part of the 13%.

The spokesperson did not identify how many people were laid off in the second half of last year. Autolus had 752 employees as of Dec. 31, according to its 2025 annual report.

Autolus plans to mostly complete the latest cuts by the third quarter and to save about $15 million on an annualized basis beginning in 2027, according to the announcement. The biotech expects its current and projected cash, cash equivalents and marketable securities will fund operations into the fourth quarter of 2027. Autolus had cash and cash equivalents of $104.1 million and marketable securities of $196.6 million as of Dec. 31, according to its annual report.

Disease Area: Oncology

Drug Type: Biologic

Source

April 29, 2026

Ascentage Pharma Group International

Neutral Outlook

Rockville, MD

501-1,000 employees

For example, the IRA includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, such as directing the federal government to negotiate a maximum fair price for certain higher-cost single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out- of-pocket prescription drug costs for beneficiaries and impose new required discounts on manufacturers, among other changes.

Disease Area: Oncology, Rare Diseases

Drug Type: Small Molecule

Source

April 28, 2026

Incyte Corp

Neutral Outlook

Wilmington, DE

1,001-5,000 employees

Further, in August 2022, the Inflation Reduction Act of 2022 was enacted, which includes provisions allowing the federal government to negotiate prices for certain high-expenditure single source Medicare drugs, to impose penalties and to implement a potential excise tax for manufacturers that fail to comply with the negotiation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law, and to impose rebate liability on manufacturers that take price increases that exceed inflation.

Disease Area: Hematology, Immune Diseases, Oncology

Drug Type: Biologic, Small Molecule

Source

April 28, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

For the second month in a row, Novartis is chipping away at its East Hanover, New Jersey, workforce. The Swiss pharma is laying off 60 employees in the city effective July 24 to Nov. 20, according to a Worker Adjustment and Retraining Notification Act (WARN) notice. Novartis is also letting go of 114 people in East Hanover from June 26 to Nov. 27, according to a March WARN alert.

Novartis also trimmed its workforce in 2025, putting 1,069 employees—including 485 in East Hanover—on the chopping block over a multiyear period. The largest round of layoffs involved 550 employees in Switzerland who will be out of work by the end of 2027.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

April 15, 2026

Transcode Therapeutics, Inc.

Neutral Outlook

South San Francisco, CA

51-200 employees

The effects of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Oncology

Drug Type: Biologic

Source

April 15, 2026

Abpro Holdings, Inc.

Neutral Outlook

San Diego, CA

51-200 employees

While the impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.

Disease Area: Oncology, Other

Drug Type: Biologic

Source

April 10, 2026

Adlai Nortye Ltd.

Neutral Outlook

Alameda, CA

1,001-5,000 employees

On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. The IRA established the Medicare Drug Price Negotiation Program, under which the Centers for Medicare & Medicaid Services, or CMS, is authorized to negotiate maximum fair prices, or MFPs, for certain high-expenditure, single-source drugs without generic or biosimilar competition.

Disease Area: Oncology

Drug Type: Small Molecule

Source

April 8, 2026

Nurix Therapeutics, Inc.

Neutral Outlook

Brisbane, CA

201-500 employees

Most notably, the Inflation Reduction Act (IRA), which was signed into law on August 16, 2022, allows Medicare to: beginning in 2026, establish a “maximum fair price” for a fixed number of pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with the Centers for Medicare and Medicaid Services (CMS); and, as of 2023, penalize drug companies that raise prices for products covered under Medicare Parts B and D faster than inflation, among other reforms.

Disease Area: Immune Diseases, Oncology

Drug Type: Small Molecule

Source

April 7, 2026

NovaBridge Biosciences

Negative Outlook

Rockville, MD

1-50 employees

Although full economic effect of the IRA on our business and the pharmaceutical industry in general is unknown at this time, it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates.

Disease Area: Oncology, Rare Diseases

Drug Type: Biologic

Source

April 6, 2026

BioNTech

Layoffs

Mainz, Rhineland-Palatinate

1,000-5,000 employees

BioNTech is closing a Singapore production plant less than four years after buying the site from Novartis to supply mRNA vaccines and therapies in the Asia-Pacific region. Last week, the Germany-based company told The Straits Times that the planned Singapore site will close by February 2027. BioNTech employs 85 people at the plant.

The company, which framed the shuttering as part of efforts to align capacity with its pipeline and long-term strategic direction, also had layoffs last year. BioNTech let go of 63 employees in August in connection with closing its cell therapy facility in Gaithersburg, Maryland. Around the same time, news broke that it would lay off 90 employees across its U.S. footprint, including 32 people at its Gaithersburg office and lab space, effective in September 2025, and 58 in Cambridge, Massachusetts.

Disease Area: Oncology

Drug Type: Biologic

Source